• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Photodynamic therapy with verteporfin combined with intravitreal injection of bevacizumab for exudative age-related macular degeneration.

作者信息

Aggio Fabio Bom, Melo Gustavo Barreto, Höfling-Lima Ana Luisa, Eid Farah Michel

出版信息

Acta Ophthalmol Scand. 2006 Dec;84(6):831-3. doi: 10.1111/j.1600-0420.2006.00764.x.

DOI:10.1111/j.1600-0420.2006.00764.x
PMID:17083553
Abstract
摘要

相似文献

1
Photodynamic therapy with verteporfin combined with intravitreal injection of bevacizumab for exudative age-related macular degeneration.维替泊芬光动力疗法联合玻璃体腔内注射贝伐单抗治疗渗出性年龄相关性黄斑变性。
Acta Ophthalmol Scand. 2006 Dec;84(6):831-3. doi: 10.1111/j.1600-0420.2006.00764.x.
2
Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration.维替泊芬联合玻璃体内注射贝伐单抗光动力疗法治疗年龄相关性黄斑变性脉络膜新生血管
Retina. 2006 Nov-Dec;26(9):988-93. doi: 10.1097/01.iae.0000247164.70376.91.
3
Necessity of paracentesis before or after intravitreal injection of bevacizumab.玻璃体内注射贝伐单抗之前或之后进行腹腔穿刺术的必要性。
Arch Ophthalmol. 2008 Sep;126(9):1314-5; author reply 1315. doi: 10.1001/archopht.126.9.1314.
4
Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration.维替泊芬治疗与玻璃体内注射贝伐单抗联合及单独应用于年龄相关性黄斑变性所致脉络膜新生血管化的研究
Ophthalmology. 2007 Jun;114(6):1179-85. doi: 10.1016/j.ophtha.2007.03.006.
5
Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone.针对年龄相关性黄斑变性所致脉络膜新生血管的三联疗法：维替泊芬光动力疗法、贝伐单抗和地塞米松。
Retina. 2007 Feb;27(2):133-40. doi: 10.1097/IAE.0b013e3180323de7.
6
Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration.玻璃体内注射贝伐单抗与维替泊芬光动力疗法治疗新生血管性年龄相关性黄斑变性的比较
Arch Ophthalmol. 2007 Oct;125(10):1357-61. doi: 10.1001/archopht.125.10.1357.
7
Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study).玻璃体内注射贝伐单抗（阿瓦斯汀）联合维替泊芬光动力疗法治疗年龄相关性黄斑变性相关脉络膜新生血管（IBeVe研究）
Graefes Arch Clin Exp Ophthalmol. 2007 Sep;245(9):1273-80. doi: 10.1007/s00417-007-0557-x. Epub 2007 Feb 28.
8
Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration.维替泊芬光动力疗法联合玻璃体内注射贝伐单抗治疗新生血管性年龄相关性黄斑变性
Ophthalmology. 2009 Apr;116(4):747-55, 755.e1. doi: 10.1016/j.ophtha.2008.12.057. Epub 2009 Feb 25.
9
Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration.光动力疗法、玻璃体内注射地塞米松和贝伐单抗同日三联疗法治疗湿性年龄相关性黄斑变性
Retina. 2009 May;29(5):573-8. doi: 10.1097/IAE.0b013e3181a46a8a.
10
Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration.玻璃体腔内注射贝伐单抗联合光动力疗法治疗新生血管性年龄相关性黄斑变性
Graefes Arch Clin Exp Ophthalmol. 2008 Jan;246(1):17-25. doi: 10.1007/s00417-007-0654-x. Epub 2007 Aug 15.

引用本文的文献

1
Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration.采用抗血管内皮生长因子疗法治疗新生血管性年龄相关性黄斑变性的抗血管生成治疗
Cochrane Database Syst Rev. 2008 Apr 16(2):CD005139. doi: 10.1002/14651858.CD005139.pub2.
2
Bevacizumab: off-label use in ophthalmology.贝伐单抗：眼科的超说明书用药
Indian J Ophthalmol. 2007 Nov-Dec;55(6):417-20. doi: 10.4103/0301-4738.36474.
3
Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration.
单次光动力疗法联合玻璃体内注射贝伐单抗和曲安奈德治疗新生血管性年龄相关性黄斑变性。
BMC Ophthalmol. 2007 Jun 7;7:10. doi: 10.1186/1471-2415-7-10.